279 related articles for article (PubMed ID: 24927996)
21. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
Jiang F; Wang HJ; Bao QC; Wang L; Jin YH; Zhang Q; Jiang D; You QD; Xu XL
Bioorg Med Chem; 2016 Nov; 24(21):5431-5439. PubMed ID: 27647369
[TBL] [Abstract][Full Text] [Related]
22. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
23. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
24. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
25. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
[TBL] [Abstract][Full Text] [Related]
27. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
28. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
29. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
30. Withaferin A targets heat shock protein 90 in pancreatic cancer cells.
Yu Y; Hamza A; Zhang T; Gu M; Zou P; Newman B; Li Y; Gunatilaka AA; Zhan CG; Sun D
Biochem Pharmacol; 2010 Feb; 79(4):542-51. PubMed ID: 19769945
[TBL] [Abstract][Full Text] [Related]
31. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
32. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
[TBL] [Abstract][Full Text] [Related]
33. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
34. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
35. Serine/Threonine Kinase Unc-51-like Kinase-1 (Ulk1) Phosphorylates the Co-chaperone Cell Division Cycle Protein 37 (Cdc37) and Thereby Disrupts the Stability of Cdc37 Client Proteins.
Li R; Yuan F; Fu W; Zhang L; Zhang N; Wang Y; Ma K; Li X; Wang L; Zhu WG; Zhao Y
J Biol Chem; 2017 Feb; 292(7):2830-2841. PubMed ID: 28073914
[TBL] [Abstract][Full Text] [Related]
36. Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines.
Zhao YR; Li HM; Zhu M; Li J; Ma T; Huo Q; Hong YS; Wu CZ
J Microbiol Biotechnol; 2018 Apr; 28(4):542-550. PubMed ID: 29618179
[TBL] [Abstract][Full Text] [Related]
37. The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy.
Sreeramulu S; Jonker HR; Langer T; Richter C; Lancaster CR; Schwalbe H
J Biol Chem; 2009 Feb; 284(6):3885-96. PubMed ID: 19073599
[TBL] [Abstract][Full Text] [Related]
38. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor.
Li T; Chen X; Dai XY; Wei B; Weng QJ; Chen X; Ouyang DF; Yan R; Huang ZJ; Jiang HL; Zhu H; Lu JJ
Toxicol Appl Pharmacol; 2017 Sep; 330():65-73. PubMed ID: 28711525
[TBL] [Abstract][Full Text] [Related]
39. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
40. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]